"In November 2021, Compass published its initial results from the study on people with treatment-resistant depression. A single dose of psilocybin, combined with therapy, was shown to have a significant effect in the short term, improving depression scores for 37 per cent of patients three weeks after the trial, with 29 per cent in remission."

https://www.ft.com/content/e8dbeaea-9b65-41ae-a86a-07e9c4058456